Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Pemazyre
Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
